scholarly journals Intrathecal rituximab for EBV-associated post-transplant lymphoproliferative disorder with central nervous system involvement unresponsive to intravenous rituximab-based treatments: a prospective study

2015 ◽  
Vol 51 (3) ◽  
pp. 456-458 ◽  
Author(s):  
M Wu ◽  
J Sun ◽  
Y Zhang ◽  
F Huang ◽  
H Zhou ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Prospective Study ◽  
Lymphoproliferative Disorder ◽  
Central Nervous System Involvement ◽  
Post Transplant ◽  
System Involvement ◽  
A Prospective Study

Intrathecal Rituximab for EBV-Associated Post-Transplant Lymphoproliferative Disorder with Central Nervous System Involvement Unresponsive to Intravenous Rituximab-Based Treatments: A Prospective Study

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 4352-4352
Author(s):  
Qifa Liu ◽  
Meiqing Wu ◽  
Jing Sun ◽  
Yu Zhang ◽  
Fen Huang ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Prospective Study ◽  
Lymphoproliferative Disorder ◽  
Conflicts Of Interest ◽  
Central Nervous System Involvement ◽  
Post Transplant ◽  
System Involvement ◽  
Dismal Prognosis ◽  
Significant Difference

Abstract Backgroud: Although the introduction of rituximab as a first-line treatment has improved outcome of post-transplant lymphoproliferative disorder (PTLD), PTLD with central nervous system involvement (CNS-PTLD) still has a dismal prognosis because of low penetrance across the blood-brain barrier. In this prospective study, we reported intrathecal rituximab was efficacy and safety in the patients with CNS-PTLD who had failed to respond to the intravenous rituximab-based treatments. Methods: From June 2009 to November 2013, 32 cases of EBV-associated PTLD were recorded in the Southern Medical University Institute of Hematology. Fourteen patients diagnosed with CNS-PTLD were enrolled in this prospective study. For the patients who failed to response to the initial intravenous rituximab-based treatments, sequential dose-escalation schedule of intrathecal rituximab (initial dose of 20mg, increased by 10mg each week and maximum dose of 50 mg) was administrated weekly. Results: Three patients were responsive and 11 were unresponsive to the initial treatments within one week after the treatments. For the 11 patients who failed to respond to the initial treatments, 9 patients received intrathecal rituximab within 7-11 days and 2 patients refused the treatment. After two cycles of rituximab-based treatments, 10 patients achieved complete response (CR), 2 patients were partial response and 2 patients were non-response. With a median follow up of 664 (range 18 to 1545) days after the diagnosis of CNS-PTLD, 7 patients survived and 7 died. The causes of death included PTLD progressing (n=3), PTLD relapse (n=1), GVHD (n=1), CMV pneumonia (n=1) and pseudomonas aeruginosa sepsis (n=1). The 3-year probability of OS was 45.7% ±14.7% in CNS-PTLD, which was no significant difference as compared to PTLD without CNS involvement(55.6% ±11.7%, P=0.706). Conclusion: Intrathecal rituximab might be an effective and safe method for CNS-PTLD in the allo-HSCT recipients who were unresponsive to the intravenous rituximab-based treatments. Disclosures No relevant conflicts of interest to declare.

Intrathecal therapy with rituximab in central nervous system involvement of post-transplant lymphoproliferative disorder

2012 ◽  
Vol 54 (3) ◽  
pp. 503-506 ◽  
Author(s):  
Krzysztof Czyzewski ◽  
Jan Styczynski ◽  
Anna Krenska ◽  
Robert Debski ◽  
Olga Zajac-Spychala ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Lymphoproliferative Disorder ◽  
Central Nervous System Involvement ◽  
Intrathecal Therapy ◽  
Post Transplant ◽  
System Involvement

scholarly journals Incidence and Prevalence of Major Central Nervous System Involvement in Systemic Lupus Erythematosus: A 3-Year Prospective Study of 370 Patients

PLoS ONE ◽  
2013 ◽  
Vol 8 (2) ◽  
pp. e55843 ◽  
Author(s):  
Eleni I. Kampylafka ◽  
Haralampos Alexopoulos ◽  
Michalis L. Kosmidis ◽  
Demosthenes B. Panagiotakos ◽  
Panayiotis G. Vlachoyiannopoulos ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Central Nervous System ◽  
Nervous System ◽  
Prospective Study ◽  
Lupus Erythematosus ◽  
Central Nervous System Involvement ◽  
Systemic Lupus ◽  
System Involvement

Fetal Central Nervous System Anomalies According to RT-PCR and Trimester of Maternal Infection with ZIKV. A Prospective Study

2020 ◽  
Author(s):  
Luz Ángela Gutiérrez-Sánchez ◽  
Carlos Hernán Becerra-Mojica ◽  
Mario Augusto Rojas ◽  
Luis Alfonso Díaz-Martínez ◽  
Luis Alfonso Pérez-Vera ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Prospective Study ◽  
Maternal Infection ◽  
Rt Pcr ◽  
A Prospective Study ◽  
Central Nervous System Anomalies

Central nervous system involvement in childhood brucellosis

2001 ◽  
Vol 21 (3) ◽  
pp. 291-292 ◽  
Author(s):  
Hüseyin Çaksen ◽  
Dursun Odabaş ◽  
Şükrü Arslan ◽  
Ahmet Faik Oner
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Central Nervous System Involvement ◽  
System Involvement
Sign in / Sign up

Export Citation Format

Share Document